Apelin
Cardiovascular / MetabolicAlso known as: APJ Ligand, Apelin-13, Apelin-36
Mechanism
A natural peptide in your body that strengthens heart contractions, dilates blood vessels, improves insulin sensitivity, and regulates fluid balance. Apelin levels decline with heart failure and aging. It comes in multiple forms (Apelin-13 is the most potent). Think of it as the body's built-in cardiac tonic.
Technical detail
Endogenous peptide ligand for the APJ receptor (now called Apelin receptor, APLNR), a class A GPCR. Derived from a 77-amino acid preproprotein, cleaved into multiple active forms: Apelin-36, Apelin-17, Apelin-13, and [Pyr1]Apelin-13 (pyroglutamated, most potent and stable). Cardiovascular: positive inotrope via PLC/IP3/Ca2+ pathway in cardiomyocytes, vasodilator via endothelial NO release, promotes angiogenesis via VEGF upregulation. Metabolic: enhances GLUT4 translocation and insulin sensitivity via AMPK activation. Renal: opposes vasopressin/ADH, promoting aquaresis. Heart failure: apelin levels inversely correlate with disease severity. ELABELA/Toddler is a second endogenous APJ ligand discovered in 2013. Phase 2 trials: MM07 (cyclic apelin analog) for pulmonary arterial hypertension.
Effects
## Detailed Effects — Apelin ### Cardiovascular System [Tier 2] - Endogenous peptide ligand for the APJ receptor (apelin receptor, now officially called APLNR). Multiple bioactive isoforms: apelin-36, apelin-17, apelin-13, and pyroglutamated apelin-13 (most potent). - Positive inotrope: increases cardiac contractility via PLCbeta-PKC-Na+/H+ exchanger and PI3K/Akt signaling in cardiomyocytes — unlike catecholamines, does NOT increase myocardial oxygen demand proportionally. - Vasodilator: NO-dependent vasodilation via endothelial APJ receptor activation. Reduces afterload and preload. - Net effect: increased cardiac output with reduced afterload — an ideal hemodynamic profile for heart failure. - Reduced apelin levels are consistently found in heart failure patients (Tier 2 data from multiple observational studies). - Apelin levels inversely correlate with disease severity in both HFrEF and HFpEF. - Apelin gene knockout mice develop progressive heart failure with age. ### Metabolic System [Tier 2] - Insulin-sensitizing effects: APJ activation on skeletal muscle enhances glucose uptake via AMPK pathway activation. - Reduces adiposity in animal models through enhanced fatty acid oxidation and energy expenditure. - Apelin levels are paradoxically elevated in obesity (possibly compensatory) but reduced in insulin resistance and type 2 diabetes. - Improves glucose tolerance in diabetic animal models. ### Renal System [Tier 2] - Counter-regulates the vasopressin/ADH system — APJ and V2R are co-expressed in renal collecting duct cells. - Apelin promotes aquaresis (water excretion without sodium loss) by antagonizing V2R-mediated AQP2 insertion. - Potential therapeutic role in hyponatremia and fluid overload states. ### Central Nervous System [Tier 2-3] - APJ receptor expressed in hypothalamus — apelin modulates food intake (anorexigenic effect at some doses), fluid homeostasis, and neuroendocrine function. - Neuroprotective effects demonstrated in stroke and neurodegenerative disease animal models. ### Pulmonary Vascular System [Tier 2] - Apelin signaling maintains pulmonary vascular homeostasis. Reduced apelin expression found in pulmonary arterial hypertension. - Loss of apelin-APJ signaling contributes to pulmonary vascular remodeling.
Practitioner Guide
## Practitioner Guide — Apelin ### Clinical Context - Apelin is an ENDOGENOUS peptide — it is NOT currently available as a therapeutic drug. - No FDA-approved apelin or APJ receptor agonist exists (as of 2026). - Multiple pharmaceutical programs are developing apelin analogs and APJ agonists for heart failure and pulmonary hypertension. - Research peptide apelin-13 and pyroglutamated apelin-13 available for laboratory use but NOT for clinical use. ### Why Practitioners Are Watching Apelin - The apelin-APJ system represents a potentially ideal heart failure target: positive inotropy WITHOUT increased oxygen demand or arrhythmia risk. - Could complement or replace existing inotropes (dobutamine, milrinone) with a better safety profile. - The metabolic benefits (insulin sensitization, anti-obesity) add value for the heart failure + diabetes overlap population. ### Strategies to Support Endogenous Apelin - **Exercise**: Both acute and chronic exercise increase circulating apelin levels. Aerobic exercise is the most reliable endogenous stimulator of the apelin system. - **Caloric restriction**: Moderate caloric restriction may increase apelin sensitivity. - **Weight management**: Obesity dysregulates apelin signaling. Weight loss normalizes apelin-APJ axis. - **Omega-3 fatty acids**: Some preclinical evidence that EPA/DHA modulate APJ receptor expression favorably. ### Research Use Only - Synthetic apelin-13: lyophilized powder, reconstitute in sterile water or PBS. Store at -20°C. - Pyroglutamated apelin-13 ([Pyr1]apelin-13): more stable, more potent — preferred for research. - Half-life in vivo: very short (<5 minutes for apelin-13 IV). This is the major challenge for therapeutic development — analogs with longer half-lives are needed. ### Monitoring Apelin as a Biomarker - Plasma apelin levels can be measured by ELISA (commercially available research-use kits). - Not yet validated as a clinical biomarker — no standardized assay or reference ranges. - Potentially useful for: HF prognostication, pulmonary hypertension risk assessment, metabolic syndrome characterization.
Research Summary
## Research Summary — Apelin ### Tier 1: Randomized Controlled Trials - **Japp et al., Circulation 2010 (n=24, crossover)**: First-in-human proof-of-concept. Apelin infusion in healthy volunteers and HF patients: increased cardiac output, reduced peripheral vascular resistance, increased coronary blood flow. No arrhythmia or adverse hemodynamic effects. Small but landmark study. - **BMS-986224 (APJ agonist) Phase 1-2**: Bristol-Myers Squibb conducted early-phase trials of an oral APJ agonist for heart failure. Results unpublished as of 2026. Multiple other pharmaceutical programs (Amgen, Novartis) have APJ agonist programs. ### Tier 2: Systematic Reviews & Key Studies - Extensive observational data (50+ studies): apelin levels are reduced in heart failure, correlate inversely with NYHA class and NT-proBNP levels, and predict outcomes. - Preclinical data is extremely robust — hundreds of animal studies showing cardioprotective, metabolic, and renal benefits. - Reviews consistently identify the apelin-APJ axis as one of the most promising cardiovascular drug targets. - Yang et al., Pharmacol Ther 2015: comprehensive review of apelin in cardiovascular disease. ### Tier 3: Case Reports & Practitioner Protocols - No established practitioner protocols for exogenous apelin administration. - Biohacker interest is emerging but extremely limited due to peptide instability and lack of practical formulations. - Some longevity physicians measure apelin levels as part of advanced biomarker panels. ### Gaps - No approved therapeutic. The short half-life of native apelin peptides is the major hurdle. - Oral APJ agonists are in development but none are approved. - Whether apelin augmentation benefits patients already on optimal HF therapy (SGLT2 inhibitors, sacubitril-valsartan) is unknown. - Apelin assay standardization needed for clinical biomarker use. ### Active Trials - Multiple APJ agonist programs in Phase 1-2 for heart failure (BMS, Amgen, Novartis). - Apelin analogs with extended half-lives in preclinical development. - Studies of apelin in pulmonary arterial hypertension.